SBI-115 is primarily utilized in the field of medical research and drug development, particularly in the study of cancer and autoimmune diseases. It functions as a novel inhibitor targeting specific pathways involved in immune regulation and tumor growth. Researchers are exploring its potential to enhance the efficacy of immunotherapies by modulating immune responses, thereby improving treatment outcomes for patients. Additionally, SBI-115 is being investigated for its role in reducing inflammation and suppressing abnormal immune activity, which could make it a promising candidate for managing chronic inflammatory conditions. Its application in preclinical studies has shown encouraging results, paving the way for further clinical trials to assess its safety and effectiveness in humans.